Uncategorized
The FDA announced the results of a new study on Medicare patients comparing Pradaxa (dabigatran etexilate mesylate; Boehringer Ingelheim Pharmaceuticals) vs. warfarin for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal (GI) bleeding, myocardial infarction (MI), and death.
News
Physician-perceived frailty and low life expectancy are the main reasons for warfarin discontinuation in elderly patients
News
For veterans receiving warfarin for nonvalvular atrial fibrillation, continuing warfarin after a diagnosis of dementia is associated with a protective effect in prevention of stroke and mortality, according to a study published online December 30 in the Journal of the American Geriatrics Society.
News
A retrospective cohort study in the Annals of Pharmacotherapy found a clinically significant decrease in warfarin dose-response with concurrent hepatitis C treatments, especially with ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV-PTV/r-DSV).
News
Machaon Diagnostics has launched a same-day genetic testing service for patients that have been prescribed warfarin (Coumadin, from Bristol-Myers Squibb).
News
Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes
Drugs in the Pipeline
CSL Behring announced results of a Phase 3b study that showed that a balanced, human 4-factor prothrombin complex concentrate (PCC) is as effective as the current standard of treatment in stopping bleeding in patients receiving vitamin K antagonist therapy (eg, warfarin).
Drugs in the Pipeline
Bristol-Myers Squib and Pfizer announced results from their Phase 3 ARISTOTLE study of Eliquis (apixaban tablet) in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke.
News
Patients with atrial fibrillation taking long-term warfarin had higher rates of dementia than non-atrial fibrillation patients, a study presented at the Heart Rhythm Society's 37th Annual Scientific Sessions has found.
Drugs in the Pipeline
Johnson & Johnson Pharmaceutical Research & Development announced results from its Phase 3 study of rivaroxaban in non-valvular atrial fibrillation (AF) patients to reduce the risk of stroke and non-CNS systemic embolism.
